Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-0934
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-08-31T06:05:05.401075Z
status: published
lens: g_space
sector: health
headline: Development of a machine-learning risk stratification tool for vasoactive medication need after two-bolus fluid resuscitation in pediatric suspected sepsis
dek: Background Timely vasopressor initiation is critical in fluid-refractory pediatric septic shock, yet clinicians lack objective tools to identify children requiring early hemodynamic escalation after fluid resuscitation. Methods We performed a retrospective multicenter study using electronic health record data from five pediatric emergency departments (March 2022-February 2025). Children aged 3 months-17 years screened for sepsis who received ≥2 fluid boluses and were vasopressor-naïve at the second bolus were in…
gain_title: A Random Forest model using eight routinely available variables predicted subsequent vasopressor need after two fluid boluses in pediatric suspected sepsis with AUROC 0.827 and stratified patients into four tiers with a 6.6% to 63.6% gradient.
problem_title: (none)
trace_subject: (none)
gain_reading: A Random Forest model using eight routinely available variables predicted subsequent vasopressor need after two fluid boluses in pediatric suspected sepsis with AUROC 0.827 and stratified patients into four tiers with a 6.6% to 63.6% gradient.
gain_evidence: Random Forest demonstrated optimal performance (AUROC 0.827 [95% CI 0.777-0.876], AUPRC 0.661) | Four risk tiers showed vasopressor rates ranging from 6.6% to 63.6%
problem_reading: (none)
problem_evidence: (none)
quick_read: Researchers developed a machine-learning risk stratification tool using routine EHR data from five pediatric emergency departments to predict need for vasoactive medication after two-bolus fluid resuscitation in suspected sepsis. Among 341 children meeting analytic criteria, 25.8% received vasopressors, and a Random Forest model achieved AUROC 0.827 and AUPRC 0.661 with four risk tiers.

The tool addresses the fluid-refractory decision point where guidelines offer limited objective guidance, potentially supporting earlier vasopressor initiation. As of the August 2026 publication, results reflect retrospective model development and internal validation, not prospective deployment or measured impact on time-to-vasopressor or outcomes.
limitation: 
tag: Evidence-backed gain
key_points: Retrospective multicenter study used EHR data from five pediatric emergency departments March 2022-February 2025. | Analytic cohort was 341 children aged 3 months-17 years screened for sepsis who received 2 fluid boluses and were vasopressor-naafve at second bolus, with 88 (25.8%) receiving vasopressors. | Eight predictors selected from 41 candidates via recursive feature elimination; super learner evaluated 13 algorithms. | Post-second-bolus mean arterial pressure and baseline MAP severity were strongest predictors; blood urea nitrogen was only retained laboratory variable.
rundown: The study included children 3 months-17 years screened for sepsis who received at least two fluid boluses and were vasopressor-naafve at the second bolus, requiring abnormal age-adjusted vital signs before first bolus and documented vitals after second. From 645 eligible patients, 341 met analytic criteria.

A super learner framework evaluated 13 algorithms after recursive feature elimination selected eight predictors from 41 candidates. Random Forest was optimal, and the model produced four calibrated risk tiers to inform the decision whether to continue fluids or escalate to vasoactive medications.
sources:
- peer_reviewed | Pediatric Research | https://doi.org/10.1038/s41390-026-05409-2 | 2026-08-29
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

c9c27dcc9e8d863e18b61cfc2877724cbddf32832c548407c41b47a1a519f951

previous

0000000000000000000000000000000000000000000000000000000000000000